New Retina Radio
New Retina Radio

07.07.25

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates

How tightly should you stick to a GA therapy’s label? Which complement inhibitor do you pick and why? And which candidates are best suited for treatment? In part 1 of this 2-part series, moderator Judy Kim, MD, and panelists Sunir Garg, MD; Deepak Sambhara, MD, and Rishi Singh, MD, explore these questions in a brief (but enlightening) discussion. 

View full description +

MORE EPISODES

10.10.25

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care

Niki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

10.09.25

The Nuts and Bolts of GA Therapy: The Opening Sessions

Charles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

09.26.25

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

09.04.25

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

Show More